When you hear the word epilepsy, what comes to mind? For many, it rsquo;s a vague image of someone having a seizure ndash; ...

Sean Lew, recommended the responsive neurostimulation procedure or RNS. "For epilepsy surgery, traditionally, the treatment is to find the part of the brain causing seizures and removing that part ...

After experiencing seizures every other week, Christine Kauzen has been seizure-free for months since receiving a rare ...

NeuroPace is known for its innovative RNS System, the first brain-responsive platform that provides personalized treatment to manage seizures in patients with drug-resistant epilepsy, potentially ...

Epilepsy is a chronic disease that causes repeated seizures caused by abnormal electrical activity caused by damaged brain cells. It affects millions of people worldwide and can disrupt their ...

(NASDAQ:NPCE), a medical device company specializing in neurological disorders, has been making significant strides in the epilepsy treatment market with its Responsive Neurostimulation (RNS ...

“We are pleased by the interest in our recent financing and the confidence it shows in our mission to transform the lives of people suffering from drug-resistant epilepsy through RNS ® therap ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

NeuroPace provides the RNS System, a brain-responsive platform that delivers personalized, real-time treatment for drug-resistant epilepsy. Disclaimer: This is an AI-generated summary of a press ...

using real-world data from children treated with RNS therapy across 27 pediatric epilepsy centers to support an expansion in indication for use; FDA submission anticipated in second half of 2025 ...

RN reviews safety, expectations ... Buchhalter, PhD MD, is the former director of the pediatric epilepsy program in the Mayo Clinic Department of Neurology, Rochester, MN.

Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net proceeds to repurchase 100% of KCK holdings and ...